Bolt Biotherapeutics(BOLT) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Reverse Stock Split Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update REDWOOD CITY, CA, August 14, 2025 – Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. "In the second quarter we focused on advancing BDC-4182, the first next-generation Boltbody™ ISA ...